1
|
Al Khatib AO, El-Tanani M, Al-Obaidi H. Inhaled Medicines for Targeting Non-Small Cell Lung Cancer. Pharmaceutics 2023; 15:2777. [PMID: 38140117 PMCID: PMC10748026 DOI: 10.3390/pharmaceutics15122777] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/24/2023] [Revised: 12/02/2023] [Accepted: 12/11/2023] [Indexed: 12/24/2023] Open
Abstract
Throughout the years, considerable progress has been made in methods for delivering drugs directly to the lungs, which offers enhanced precision in targeting specific lung regions. Currently, for treatment of lung cancer, the prevalent routes for drug administration are oral and parenteral. These methods, while effective, often come with side effects including hair loss, nausea, vomiting, susceptibility to infections, and bleeding. Direct drug delivery to the lungs presents a range of advantages. Notably, it can significantly reduce or even eliminate these side effects and provide more accurate targeting of malignancies. This approach is especially beneficial for treating conditions like lung cancer and various respiratory diseases. However, the journey towards perfecting inhaled drug delivery systems has not been without its challenges, primarily due to the complex structure and functions of the respiratory tract. This comprehensive review will investigate delivery strategies that target lung cancer, specifically focusing on non-small-cell lung cancer (NSCLC)-a predominant variant of lung cancer. Within the scope of this review, active and passive targeting techniques are covered which highlight the roles of advanced tools like nanoparticles and lipid carriers. Furthermore, this review will shed light on the potential synergies of combining inhalation therapy with other treatment approaches, such as chemotherapy and immunotherapy. The goal is to determine how these combinations might amplify therapeutic results, optimizing patient outcomes and overall well-being.
Collapse
Affiliation(s)
- Arwa Omar Al Khatib
- School of Pharmacy, University of Reading, Reading RG6 6AD, UK
- Faculty of Pharmacy, Al Ahliyya Amman University, Amman 19111, Jordan
| | - Mohamed El-Tanani
- Faculty of Pharmacy, Al Ahliyya Amman University, Amman 19111, Jordan
- College of Pharmacy, RAK Medical and Health Sciences University, Ras Al Khaimah P.O. Box 11172, United Arab Emirates
| | | |
Collapse
|
2
|
Ahalwat S, Bhatt DC, Rohilla S, Jogpal V, Sharma K, Virmani T, Kumar G, Alhalmi A, Alqahtani AS, Noman OM, Almoiliqy M. Mannose-Functionalized Isoniazid-Loaded Nanostructured Lipid Carriers for Pulmonary Delivery: In Vitro Prospects and In Vivo Therapeutic Efficacy Assessment. Pharmaceuticals (Basel) 2023; 16:1108. [PMID: 37631023 PMCID: PMC10458796 DOI: 10.3390/ph16081108] [Citation(s) in RCA: 3] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/26/2023] [Revised: 07/23/2023] [Accepted: 08/01/2023] [Indexed: 08/27/2023] Open
Abstract
Resistance to isoniazid (INH) is common and increases the possibility of acquiring multidrug-resistant tuberculosis. For this study, isoniazid-loaded nanostructured lipid carriers (INH-NLCs) were developed and effectively functionalized with mannose (Man) to enhance the residence time of the drug within the lungs via specific delivery and increase the therapeutic efficacy of the formulation. The mannose-functionalized isoniazid-loaded nanostructured lipid carrier (Man-INH-NLC) formulation was evaluated with respect to various formulation parameters, namely, encapsulation efficiency (EE), drug loading (DL), average particle size (PS), zeta potential (ZP), polydispersity index (PDI), in vitro drug release (DR), and release kinetics. The in vitro inhalation behavior of the developed formulation after nebulization was investigated using an Andersen cascade impactor via the estimation of the mass median aerosolized diameter (MMAD) and geometric aerodynamic diameter (GAD) and subsequently found to be suitable for effective lung delivery. An in vivo pharmacokinetic study was carried out in a guinea pig animal model, and it was demonstrated that Man-INH-NLC has a longer residence time in the lungs with improved pharmacokinetics when compared with unfunctionalized INH-NLC, indicating the enhanced therapeutic efficacy of the Man-INH-NLC formulation. Histopathological analysis led us to determine that the extent of tissue damage was more severe in the case of the pure drug solution of isoniazid compared to the Man-INH-NLC formulation after nebulization. Thus, the nebulization of Man-INH-NLC was found to be safe, forming a sound basis for enhancing the therapeutic efficacy of the drug for improved management in the treatment of pulmonary tuberculosis.
Collapse
Affiliation(s)
- Shaveta Ahalwat
- School of Medical and Allied Sciences, G. D. Goenka University, Gurugram 122103, India; (V.J.); (K.S.)
| | - Dinesh Chandra Bhatt
- Department of Pharmaceutical Sciences, Guru Jambheshwar University of Science and Technology, Hisar 125001, India;
| | - Surbhi Rohilla
- Department of Pharmaceutical Sciences, Guru Jambheshwar University of Science and Technology, Hisar 125001, India;
| | - Vikas Jogpal
- School of Medical and Allied Sciences, G. D. Goenka University, Gurugram 122103, India; (V.J.); (K.S.)
| | - Kirti Sharma
- School of Medical and Allied Sciences, G. D. Goenka University, Gurugram 122103, India; (V.J.); (K.S.)
| | - Tarun Virmani
- School of Pharmaceutical Sciences, MVN University, Palwal 121105, India; (T.V.); (G.K.)
| | - Girish Kumar
- School of Pharmaceutical Sciences, MVN University, Palwal 121105, India; (T.V.); (G.K.)
| | - Abdulsalam Alhalmi
- Department of Pharmaceutics, School of Pharmaceutical Education and Research, Jamia Hamdard, New Delhi 110062, India;
| | - Ali S. Alqahtani
- Department of Pharmacognosy, College of Pharmacy, King Saud University, P.O. Box 2457, Riyadh 11451, Saudi Arabia; (A.S.A.); (O.M.N.)
| | - Omar M. Noman
- Department of Pharmacognosy, College of Pharmacy, King Saud University, P.O. Box 2457, Riyadh 11451, Saudi Arabia; (A.S.A.); (O.M.N.)
| | - Marwan Almoiliqy
- Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA;
| |
Collapse
|
3
|
Development and Optimisation of Inhalable EGCG Nano-Liposomes as a Potential Treatment for Pulmonary Arterial Hypertension by Implementation of the Design of Experiments Approach. Pharmaceutics 2023; 15:pharmaceutics15020539. [PMID: 36839861 PMCID: PMC9965461 DOI: 10.3390/pharmaceutics15020539] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/31/2022] [Revised: 11/14/2022] [Accepted: 01/25/2023] [Indexed: 02/09/2023] Open
Abstract
Epigallocatechin gallate (EGCG), the main ingredient in green tea, holds promise as a potential treatment for pulmonary arterial hypertension (PAH). However, EGCG has many drawbacks, including stability issues, low bioavailability, and a short half-life. Therefore, the purpose of this research was to develop and optimize an inhalable EGCG nano-liposome formulation aiming to overcome EGCG's drawbacks by applying a design of experiments strategy. The aerodynamic behaviour of the optimum formulation was determined using the next-generation impactor (NGI), and its effects on the TGF-β pathway were determined using a cell-based reporter assay. The newly formulated inhalable EGCG liposome had an average liposome size of 105 nm, a polydispersity index (PDI) of 0.18, a zeta potential of -25.5 mV, an encapsulation efficiency of 90.5%, and a PDI after one month of 0.19. These results are in complete agreement with the predicted values of the model. Its aerodynamic properties were as follows: the mass median aerodynamic diameter (MMAD) was 4.41 µm, the fine particle fraction (FPF) was 53.46%, and the percentage of particles equal to or less than 3 µm was 34.3%. This demonstrates that the novel EGCG liposome has all the properties required to be inhalable, and it is expected to be deposited deeply in the lung. The TGFβ pathway is activated in PAH lungs, and the optimum EGCG nano-liposome inhibits TGFβ signalling in cell-based studies and thus holds promise as a potential treatment for PAH.
Collapse
|
4
|
Zhang YB, Xu D, Bai L, Zhou YM, Zhang H, Cui YL. A Review of Non-Invasive Drug Delivery through Respiratory Routes. Pharmaceutics 2022; 14:pharmaceutics14091974. [PMID: 36145722 PMCID: PMC9506287 DOI: 10.3390/pharmaceutics14091974] [Citation(s) in RCA: 4] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/07/2022] [Revised: 09/14/2022] [Accepted: 09/16/2022] [Indexed: 11/24/2022] Open
Abstract
With rapid and non-invasive characteristics, the respiratory route of administration has drawn significant attention compared with the limitations of conventional routes. Respiratory delivery can bypass the physiological barrier to achieve local and systemic disease treatment. A scientometric analysis and review were used to analyze how respiratory delivery can contribute to local and systemic therapy. The literature data obtained from the Web of Science Core Collection database showed an increasing worldwide tendency toward respiratory delivery from 1998 to 2020. Keywords analysis suggested that nasal and pulmonary drug delivery are the leading research topics in respiratory delivery. Based on the results of scientometric analysis, the research hotspots mainly included therapy for central nervous systems (CNS) disorders (Parkinson’s disease, Alzheimer’s disease, depression, glioblastoma, and epilepsy), tracheal and bronchial or lung diseases (chronic obstructive pulmonary disease, asthma, acute lung injury or respiratory distress syndrome, lung cancer, and idiopathic pulmonary fibrosis), and systemic diseases (diabetes and COVID-19). The study of advanced preparations contained nano drug delivery systems of the respiratory route, drug delivery barriers investigation (blood-brain barrier, BBB), and chitosan-based biomaterials for respiratory delivery. These results provided researchers with future research directions related to respiratory delivery.
Collapse
Affiliation(s)
- Yong-Bo Zhang
- State Key Laboratory of Component-Based Chinese Medicine, Research Center of Traditional Chinese Medicine, Tianjin University of Traditional Chinese Medicine, Tianjin 301617, China
- Haihe Laboratory of Modern Chinese Medicine, Tianjin 301617, China
| | - Dong Xu
- State Key Laboratory of Component-Based Chinese Medicine, Research Center of Traditional Chinese Medicine, Tianjin University of Traditional Chinese Medicine, Tianjin 301617, China
- Haihe Laboratory of Modern Chinese Medicine, Tianjin 301617, China
- Correspondence: (D.X.); (Y.-L.C.)
| | - Lu Bai
- State Key Laboratory of Component-Based Chinese Medicine, Research Center of Traditional Chinese Medicine, Tianjin University of Traditional Chinese Medicine, Tianjin 301617, China
- Haihe Laboratory of Modern Chinese Medicine, Tianjin 301617, China
| | - Yan-Ming Zhou
- State Key Laboratory of Component-Based Chinese Medicine, Research Center of Traditional Chinese Medicine, Tianjin University of Traditional Chinese Medicine, Tianjin 301617, China
- Haihe Laboratory of Modern Chinese Medicine, Tianjin 301617, China
| | - Han Zhang
- State Key Laboratory of Component-Based Chinese Medicine, Research Center of Traditional Chinese Medicine, Tianjin University of Traditional Chinese Medicine, Tianjin 301617, China
- Haihe Laboratory of Modern Chinese Medicine, Tianjin 301617, China
| | - Yuan-Lu Cui
- State Key Laboratory of Component-Based Chinese Medicine, Research Center of Traditional Chinese Medicine, Tianjin University of Traditional Chinese Medicine, Tianjin 301617, China
- Haihe Laboratory of Modern Chinese Medicine, Tianjin 301617, China
- Correspondence: (D.X.); (Y.-L.C.)
| |
Collapse
|
5
|
Zhu P, Cai L, Liu Q, Feng S, Ruan H, Zhang L, Zhou L, Jiang H, Wang H, Wang J, Chen J. One-pot synthesis of α-Linolenic acid nanoemulsion-templated drug-loaded silica mesocomposites as efficient bactericide against drug-resistant Mycobacterium tuberculosis. Eur J Pharm Sci 2022; 176:106261. [PMID: 35840102 DOI: 10.1016/j.ejps.2022.106261] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/04/2022] [Revised: 07/10/2022] [Accepted: 07/11/2022] [Indexed: 12/15/2022]
Abstract
Nowadays, pathogenic infection has posed a severe threat to the public health and environmental sanitation, urging a continuous search of efficacious and safe bactericidal agents of various formulated forms. Here, a facile one-pot hydrothermal preparation of mesoporous silica nanoparticles using ultrasonication-assisted nanoemulsion of α-Linolenic acid (α-LA) as template was developed. The formed silica mesocomposite at water/fatty-acid surface provides an easy yet green synthesis route, which can be generalized for the further encapsulation of hydrophobic drugs such as antimycobacterial Rifampicin (RIF). The obtained α-LA nanoemulsion-templated silica nanoparticles (LNS NPs), with a weight content of ∼17% α-LA in the composite, showed apparent antibacterial effect against Staphylococcus aureus (S. aureus). By comparison, the removal of α-LA from the silica nanoparticles (LNS-1 NPs) resulted in the composite of enlarged pore size with negligible bactericidal activities. Notably, the Isoniazide (INH) and Rifampicin (RIF)-encapsulated LNS NPs exhibited outstanding antimycobacterial activity against both drug-sensitive and drug-resistant Mycobacterium tuberculosis (M. tuberculosis). The obtained highly biocompatible, biosafe and low-energy consumptive α-LA-contained mesostructured silica-based bactericide holds promising therapeutic potentials to tackle the emerging drug-resistant infectious microbes.
Collapse
Affiliation(s)
- Ping Zhu
- Center for Global Health, School of Public Health, Nanjing Medical University, Nanjing 211166, China
| | - Ling Cai
- Center for Global Health, School of Public Health, Nanjing Medical University, Nanjing 211166, China
| | - Qiao Liu
- Center for Global Health, School of Public Health, Nanjing Medical University, Nanjing 211166, China; Department of Chronic Communicable Disease, Center for Disease Control and Prevention of Jiangsu Province, Nanjing, China
| | - Shanwu Feng
- Women's Hospital of Nanjing Medical University, Nanjing Maternity and Child Health Care Hospital, 123 Tianfei Lane, Nanjing 210004, China
| | - Hongjie Ruan
- Women's Hospital of Nanjing Medical University, Nanjing Maternity and Child Health Care Hospital, 123 Tianfei Lane, Nanjing 210004, China
| | - Li Zhang
- Center for Global Health, School of Public Health, Nanjing Medical University, Nanjing 211166, China
| | - Liuzhu Zhou
- Center for Global Health, School of Public Health, Nanjing Medical University, Nanjing 211166, China
| | - Huijun Jiang
- School of Pharmacy, Nanjing Medical University, Nanjing 211166, China
| | - Hongsheng Wang
- Center for Global Health, School of Public Health, Nanjing Medical University, Nanjing 211166, China; Institute of Dermatology, Chinese Academy of Medical Sciences and Peking Union Medical College, St. 12 Jiangwangmiao, Nanjing 210042, China.
| | - Jianming Wang
- Center for Global Health, School of Public Health, Nanjing Medical University, Nanjing 211166, China.
| | - Jin Chen
- Center for Global Health, School of Public Health, Nanjing Medical University, Nanjing 211166, China; Jiangsu Province Engineering Research Center of Antibody Drug, Key Laboratory of Antibody Technique of National Health Commission, Nanjing Medical University, Nanjing 211166, China; The Key Laboratory of Modern Toxicology, Ministry of Education, School of Public Health, Nanjing Medical University, Nanjing 211166, China; Xinjiang Production & Construction Corps Key Laboratory of Protection and Utilization of Biological Resources in Tarim Basin, Tarim University, Alar 843300, China.
| |
Collapse
|
6
|
Said-Elbahr R, Nasr M, Alhnan MA, Taha I, Sammour O. Simultaneous pulmonary administration of celecoxib and naringin using a nebulization-friendly nanoemulsion: A device-targeted delivery for treatment of lung cancer. Expert Opin Drug Deliv 2022; 19:611-622. [PMID: 35538642 DOI: 10.1080/17425247.2022.2076833] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
Abstract
BACKGROUND Lung cancer is a principal cause of death worldwide, and its treatment is very challenging. Nebulization offers a promising means of targeting drugs to their site of action in the lung. RESEARCH DESIGN AND METHODS In the present study, nebulizable oil in water nanoemulsion formulations were co-loaded with naringin/celecoxib, and tested for pulmonary administration by different nebulizer types. RESULTS : The translucent appearance of nanoemulsion formulations was revealed, with particle size (75-106 nm), zeta potential (-3.42 to -4.86 mV), and controlled in-vitro release profiles for both drugs. The nanoemulsions showed favourable stability profiles, and superior cytotoxicity on A549 lung cancer cells. Aerosolization studies on the selected nanoemulsion formulation revealed its high stability during nebulization, with the generation of an aerosol of small volume median diameter, and mass median aerodynamic diameter lower than 5 µm. Moreover, it demonstrated considerable safety and bioaccumulation in lung tissues, in addition to accumulation in the brain, liver and bones which are the main organs to which lung cancer metastasizes. CONCLUSIONS Nanoemulsion proved to be a promising nebulizable system, which paves the way for treatment of pulmonary diseases other than lung cancer.
Collapse
Affiliation(s)
- Ramy Said-Elbahr
- Department of Pharmaceutics and Industrial Pharmacy, Faculty of Pharmacy, Ain Shams University, Cairo, Egypt.,School of Pharmacy and Biomedical Sciences, University of Central Lancashire, Preston, UK
| | - Maha Nasr
- Department of Pharmaceutics and Industrial Pharmacy, Faculty of Pharmacy, Ain Shams University, Cairo, Egypt
| | - Mohamed A Alhnan
- School of Pharmacy and Biomedical Sciences, University of Central Lancashire, Preston, UK.,Institute of Pharmaceutical Science, King's College London, London, UK
| | - Ismail Taha
- Hot lab. Centre, Atomic Energy Authority, Cairo, Egypt.,Faculty of Pharmacy, AL Bayan University, Baghdad, Iraq
| | - Omaima Sammour
- Department of Pharmaceutics and Industrial Pharmacy, Faculty of Pharmacy, Ain Shams University, Cairo, Egypt
| |
Collapse
|
7
|
Studies in Development and Statistical Optimization of Levofloxacin Solid Lipid Nanoparticles for the Treatment of Tuberculosis. J Pharm Innov 2022. [DOI: 10.1007/s12247-022-09617-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
|
8
|
Emami A, Babaei E, Nagishbandi A, Azeez HJ, Feizi MAH, Golizadeh A. Cellular uptake and apoptotic properties of gemini curcumin in gastric cancer cells. Mol Biol Rep 2021; 48:7215-7222. [PMID: 34623595 DOI: 10.1007/s11033-021-06713-2] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/03/2020] [Accepted: 09/19/2021] [Indexed: 01/09/2023]
Abstract
INTRODUCTION Curcumin is a polyphenolic natural compound, which has demonstrated to possess antioxidant, anti-inflammatory, and anticancer effects in vitro & in vivo. However, its applicability in cancer therapy has been limited due to its poor cellular uptake. Here, we aimed to evaluate the anticancer effect of novel gemini curcumin (Gemini-Cur) on the gastric cancer AGS cells. METHOD The AGS cancerous and HFF-2 non-cancerous cells were treated with Gemini-Cur and curcumin (Cur) in a time- and dose-dependent manner. Cellular toxicity was studied using MTT, fluorescence microscopy, annexin V/FITC, and cell cycle assays. Additionally, real-time PCR and western blotting were employed to evaluate the expression of Bax, Bcl-2 and survivin genes. RESULTS Our data indicated that Gemini-Cur is significantly taken into AGS cells compared to Cur. Moreover, the viability of Gemini-Cur treated cells was significantly reduced in a time- and dose-dependent manner (p < 0.001). Gemini-Cur compound induced G2/M cell cycle arrest that was followed by apoptosis in a time-dependent manner (p < 0.0001). DISCUSSION Taken together, our findings support the idea that Gemini-Cur has the potential to be considered as an anticancer agent.
Collapse
Affiliation(s)
- Ali Emami
- Department of Animal Biology, School of Natural Sciences, University of Tabriz, 51555, Tabriz, Iran
| | - Esmaeil Babaei
- Department of Animal Biology, School of Natural Sciences, University of Tabriz, 51555, Tabriz, Iran.
| | - Alaadin Nagishbandi
- Department of Pharmacognosy, College of Pharmacy, Hawler Medical University, Kurdistan Region, Erbil, Iraq
| | - Hewa Jalal Azeez
- Department of Animal Biology, School of Natural Sciences, University of Tabriz, 51555, Tabriz, Iran
| | | | - Ashraf Golizadeh
- Department of Animal Biology, School of Natural Sciences, University of Tabriz, 51555, Tabriz, Iran
| |
Collapse
|
9
|
Freitas MM, Cavalcante PM, Duarte-Filho LAMS, Macedo CAF, Brito MC, Menezes PMN, Ribeiro TF, Costa SM, Carvalho BAG, Ribeiro FPRA, Moura MPS, Silva FS, Ribeiro LAA. Investigation of the relaxing effect of a camphor nanoemulsion on rat isolated trachea. Chem Biol Interact 2021; 348:109656. [PMID: 34516975 DOI: 10.1016/j.cbi.2021.109656] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/27/2020] [Revised: 07/15/2021] [Accepted: 09/09/2021] [Indexed: 10/20/2022]
Abstract
Asthma is a chronic inflammatory disease that targeting lower airways, being characterized by bronchial smooth muscle hyper responsiveness and mucus hypersecretion. Asthma is considered the most common respiratory disease in the world, affecting approximately 235 million individuals. The main therapy sometimes fails to establish clinical improvement in patients, which leads to a constant search for new alternatives. Camphor is a transparent solid monoterpene with a strong aroma, which due to its high lipophilicity is insoluble in water. Nanostructured carrier systems have shown promise as a delivery system for lipophilic compounds such as monoterpenes. Therefore, the objective of this work was to evaluate the relaxant effect of nanoemulsified camphor (NEC), as well as the mechanism of action of that monoterpene, in isolated rat trachea. The results obtained demonstrated that NEC promote relaxation of the isolated rat trachea when smooth muscle contraction was induced by both carbachol (CCh) and KCl, presenting a pCE50 of 2.25 ± 0.27 and 3.30 ± 0.07, respectively. In the presence of dexamethasone (DEXA), tetraethylammonium (TEA), glibenclamide (GLIB), 1H-[1,2,4]-oxadiazole-[4,3,-a]-quinoxaline-1-one (ODQ) and ruthenium red (RR) there was a significant difference in at least one of the evaluated pharmacological parameters, such as concentration-response curves shape, Emax or pCE50. As conclusion, NEC may be involved with β-adrenergic receptors, channels for K+ sensitive to ATP (KATP) or Channels for K+ opened by Ca2+ (KCa), increase in prostanoids and with receptor channel with transient potential (TRPv). In conclusion, β-adrenergic receptors, prostanoids, nitric oxide (NO), ATP-sensitive K+ channels (KATP), Ca2+-opened K+ channels (KCa), and transient receptor potential cation channel subfamily V (TRPV) are involved in the relaxing effect of NEC. In addition, the mechanism of action of NEC may be involved with the signal transduction pathway Nitric Oxide/soluble guanylyl cyclase/cGMP/cGMP-activated protein kinase. NEC, therefore, demonstrates spasmolytic activity when presenting tracheal relaxation compared to CCh and KCl contracturants.
Collapse
Affiliation(s)
- Maíra M Freitas
- Programa de Pós-Graduação em Biociências (PPGB), Universidade Federal do Vale do São Francisco (UNIVASF), Campus Centro, Av. José de Sá Maniçoba, S/N, Cx. Postal 252, CEP: 56.304-205, Petrolina-PE, Brazil
| | - Pedro M Cavalcante
- Programa de Pós-Graduação em Biociências (PPGB), Universidade Federal do Vale do São Francisco (UNIVASF), Campus Centro, Av. José de Sá Maniçoba, S/N, Cx. Postal 252, CEP: 56.304-205, Petrolina-PE, Brazil
| | - Luiz A M S Duarte-Filho
- Programa de Pós-Graduação em Biociências (PPGB), Universidade Federal do Vale do São Francisco (UNIVASF), Campus Centro, Av. José de Sá Maniçoba, S/N, Cx. Postal 252, CEP: 56.304-205, Petrolina-PE, Brazil
| | - Cicero A F Macedo
- Programa de Pós-graduação em Biotecnologia, Universidade Estadual de Feira de Santana (UEFS), Av. Transnordestina, S/N, Novo Horizonte, CEP: 44036-900, Feira de Santana-Ba, Brazil
| | - Mariana C Brito
- Programa de Pós-graduação em Biotecnologia, Universidade Estadual de Feira de Santana (UEFS), Av. Transnordestina, S/N, Novo Horizonte, CEP: 44036-900, Feira de Santana-Ba, Brazil
| | - Pedro M N Menezes
- Rede Nordeste de Biotecnologia (RENORBIO), Universidade Federal Rural de Pernambuco (UFRPE), Rua Dom Manuel de Medeiros, S/N, Dois Irmãos, CEP: 52171-900, Recife-PE, Brazil
| | - Thiago F Ribeiro
- Rede Nordeste de Biotecnologia (RENORBIO), Universidade Federal Rural de Pernambuco (UFRPE), Rua Dom Manuel de Medeiros, S/N, Dois Irmãos, CEP: 52171-900, Recife-PE, Brazil
| | - Sâmara M Costa
- Curso de Graduação em Farmácia, Universidade Federal do Vale do São Francisco (UNIVASF), Campus Centro, Av. José de Sá Maniçoba, S/N, Cx. Postal 252, CEP: 56.304-205, Petrolina-PE, Brazil
| | - Bárbara A G Carvalho
- Curso de Graduação em Farmácia, Universidade Federal do Vale do São Francisco (UNIVASF), Campus Centro, Av. José de Sá Maniçoba, S/N, Cx. Postal 252, CEP: 56.304-205, Petrolina-PE, Brazil
| | - Fernanda P R A Ribeiro
- Colegiado de Ciências Farmacêuticas (CFARM), Laboratório de Farmacologia Experimental (LAFEX), Universidade Federal do Vale do São Francisco (UNIVASF), Campus Centro, Av. José de Sá Maniçoba, S/N, Cx. Postal 252, CEP: 56.304-205, Petrolina-PE, Brazil
| | - Marigilson P S Moura
- Programa de Pós-Graduação em Biociências (PPGB), Colegiado de Ciências Farmacêuticas (CFARM), Universidade Federal do Vale do São Francisco (UNIVASF), Campus Centro, Av. José de Sá Maniçoba, S/N, Cx. Postal 252, CEP: 56.304-205, Petrolina-PE, Brazil
| | - Fabricio S Silva
- Programa de Pós-Graduação em Biociências (PPGB), Colegiado de Ciências Farmacêuticas (CFARM), Universidade Federal do Vale do São Francisco (UNIVASF), Campus Centro, Av. José de Sá Maniçoba, S/N, Cx. Postal 252, CEP: 56.304-205, Petrolina-PE, Brazil
| | - Luciano A A Ribeiro
- Programa de Pós-Graduação em Biociências (PPGB), Colegiado de Ciências Farmacêuticas (CFARM), Universidade Federal do Vale do São Francisco (UNIVASF), Campus Centro, Av. José de Sá Maniçoba, S/N, Cx. Postal 252, CEP: 56.304-205, Petrolina-PE, Brazil.
| |
Collapse
|
10
|
Abdulbaqi IM, Assi RA, Yaghmur A, Darwis Y, Mohtar N, Parumasivam T, Saqallah FG, Wahab HA. Pulmonary Delivery of Anticancer Drugs via Lipid-Based Nanocarriers for the Treatment of Lung Cancer: An Update. Pharmaceuticals (Basel) 2021; 14:725. [PMID: 34451824 PMCID: PMC8400724 DOI: 10.3390/ph14080725] [Citation(s) in RCA: 17] [Impact Index Per Article: 5.7] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/01/2021] [Revised: 07/19/2021] [Accepted: 07/20/2021] [Indexed: 12/24/2022] Open
Abstract
Lung cancer (LC) is the leading cause of cancer-related deaths, responsible for approximately 18.4% of all cancer mortalities in both sexes combined. The use of systemic therapeutics remains one of the primary treatments for LC. However, the therapeutic efficacy of these agents is limited due to their associated severe adverse effects, systemic toxicity and poor selectivity. In contrast, pulmonary delivery of anticancer drugs can provide many advantages over conventional routes. The inhalation route allows the direct delivery of chemotherapeutic agents to the target LC cells with high local concertation that may enhance the antitumor activity and lead to lower dosing and fewer systemic toxicities. Nevertheless, this route faces by many physiological barriers and technological challenges that may significantly affect the lung deposition, retention, and efficacy of anticancer drugs. The use of lipid-based nanocarriers could potentially overcome these problems owing to their unique characteristics, such as the ability to entrap drugs with various physicochemical properties, and their enhanced permeability and retention (EPR) effect for passive targeting. Besides, they can be functionalized with different targeting moieties for active targeting. This article highlights the physiological, physicochemical, and technological considerations for efficient inhalable anticancer delivery using lipid-based nanocarriers and their cutting-edge role in LC treatment.
Collapse
Affiliation(s)
- Ibrahim M. Abdulbaqi
- School of Pharmaceutical Sciences, Universiti Sains Malaysia, Minden, Penang 11800, Malaysia; (I.M.A.); (R.A.A.); (N.M.); (T.P.); (F.G.S.)
- College of Pharmacy, Al-Kitab University, Altun kupri, Kirkuk 36001, Iraq
| | - Reem Abou Assi
- School of Pharmaceutical Sciences, Universiti Sains Malaysia, Minden, Penang 11800, Malaysia; (I.M.A.); (R.A.A.); (N.M.); (T.P.); (F.G.S.)
- College of Pharmacy, Al-Kitab University, Altun kupri, Kirkuk 36001, Iraq
| | - Anan Yaghmur
- Department of Pharmacy, Faculty of Health and Medical Sciences, University of Copenhagen, Universitetsparken 2, DK-2100 Copenhagen Ø, Denmark;
| | - Yusrida Darwis
- School of Pharmaceutical Sciences, Universiti Sains Malaysia, Minden, Penang 11800, Malaysia; (I.M.A.); (R.A.A.); (N.M.); (T.P.); (F.G.S.)
| | - Noratiqah Mohtar
- School of Pharmaceutical Sciences, Universiti Sains Malaysia, Minden, Penang 11800, Malaysia; (I.M.A.); (R.A.A.); (N.M.); (T.P.); (F.G.S.)
| | - Thaigarajan Parumasivam
- School of Pharmaceutical Sciences, Universiti Sains Malaysia, Minden, Penang 11800, Malaysia; (I.M.A.); (R.A.A.); (N.M.); (T.P.); (F.G.S.)
| | - Fadi G. Saqallah
- School of Pharmaceutical Sciences, Universiti Sains Malaysia, Minden, Penang 11800, Malaysia; (I.M.A.); (R.A.A.); (N.M.); (T.P.); (F.G.S.)
| | - Habibah A. Wahab
- School of Pharmaceutical Sciences, Universiti Sains Malaysia, Minden, Penang 11800, Malaysia; (I.M.A.); (R.A.A.); (N.M.); (T.P.); (F.G.S.)
| |
Collapse
|
11
|
Araújo-Filho HGD, Dos Santos JF, Carvalho MTB, Picot L, Fruitier-Arnaudin I, Groult H, Quintans-Júnior LJ, Quintans JSS. Anticancer activity of limonene: A systematic review of target signaling pathways. Phytother Res 2021; 35:4957-4970. [PMID: 33864293 DOI: 10.1002/ptr.7125] [Citation(s) in RCA: 15] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/21/2020] [Revised: 02/26/2021] [Accepted: 03/26/2021] [Indexed: 02/06/2023]
Abstract
Limonene (LIM) is a monoterpene, which is abundant in essential oils of Citrus fruits peels (Rutaceae). More recently, LIM, as a potential natural anticancer compound, has attracted major attention and exerted a chemopreventive activity, stimulating the detoxification of carcinogenic compounds and limiting tumor growth and angiogenesis in various cancer models. Twenty-six (26) articles were selected based on previously established criteria. Anticancer activity of LIM was related to the inhibition of tumor initiation, growth, and angiogenesis and the induction of cancer cells apoptosis. LIM was able to increase Bax expression, release cytochrome c, and activate the caspase pathway. In addition, LIM increased the expression of p53 and decreased the activity of Ras/Raf/MEK/ERK and PI3K/Akt pathways. LIM also decreased the expression of VEGF and increased the activities of the Man-6-P / IGF2R and TGF-βIIR receptors. These results highlight LIM as an abundant natural molecule with low toxicity and pleiotropic pharmacological activity in cancer cells, targeting various cell-signaling pathways critically involved in the initiation, growth, and chemoresistance of cancer cells.
Collapse
Affiliation(s)
- Heitor Gomes de Araújo-Filho
- Laboratory of Neuroscience and Pharmacological Assays (LANEF), Department of Physiology, Federal University of Sergipe, São Cristóvão, Brazil
| | - Jucilene F Dos Santos
- Laboratory of Neuropharmacology and Integrative Physiology (LNFI), Department of Physiology, Federal University of Alagoas, Maceió, Brazil
| | - Mikaella T B Carvalho
- Laboratory of Neuroscience and Pharmacological Assays (LANEF), Department of Physiology, Federal University of Sergipe, São Cristóvão, Brazil.,Postgraduate Health Sciences Program (PPGCS), Federal University of Sergipe, São Cristóvão, Brazil
| | - Laurent Picot
- UMRi CNRS 7266 LIENSs, University of La Rochelle, La Rochelle, France
| | | | - Hugo Groult
- UMRi CNRS 7266 LIENSs, University of La Rochelle, La Rochelle, France
| | - Lucindo J Quintans-Júnior
- Laboratory of Neuroscience and Pharmacological Assays (LANEF), Department of Physiology, Federal University of Sergipe, São Cristóvão, Brazil.,Postgraduate Health Sciences Program (PPGCS), Federal University of Sergipe, São Cristóvão, Brazil
| | - Jullyana S S Quintans
- Laboratory of Neuroscience and Pharmacological Assays (LANEF), Department of Physiology, Federal University of Sergipe, São Cristóvão, Brazil.,Postgraduate Health Sciences Program (PPGCS), Federal University of Sergipe, São Cristóvão, Brazil
| |
Collapse
|
12
|
Nagoor Meeran M, Seenipandi A, Javed H, Sharma C, Hashiesh HM, Goyal SN, Jha NK, Ojha S. Can limonene be a possible candidate for evaluation as an agent or adjuvant against infection, immunity, and inflammation in COVID-19? Heliyon 2021; 7:e05703. [PMID: 33490659 PMCID: PMC7810623 DOI: 10.1016/j.heliyon.2020.e05703] [Citation(s) in RCA: 12] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/04/2019] [Revised: 09/16/2020] [Accepted: 12/08/2020] [Indexed: 01/08/2023] Open
Abstract
Coronavirus disease (COVID-19) caused by novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is an ongoing pandemic and presents a public health emergency. It has affected millions of people and continues to affect more, despite the tremendous social preventive measures. The therapeutic strategy relies on suppressing infectivity and inflammation, along with immune modulation. The identification of candidate drugs effective for COVID-19 is crucial, thus many natural products including phytochemicals are also being proposed for repurposing and evaluated for their potential in COVID-19. Among numerous phytochemicals, limonene (LMN), a dietary terpene of natural origin has been recently showed to target viral proteins in the in-silico studies. LMN is one of the main compounds identified in many citrus plants, available and accessible in diets and well-studied for its therapeutic benefits. Due to dietary nature, relative safety and efficacy along with favorable physicochemical properties, LMN has been suggested to be a fascinating candidate for further investigation in COVID-19. LMN showed to modulate numerous signaling pathways and inhibits inflammatory mediators, including cytokines, chemokines, adhesion molecules, prostanoids, and eicosanoids. We hypothesized that given the pathogenesis of COVID-19 involving infection, inflammation, and immunity, LMN may have potential to limit the severity and progression of the disease owing to its immunomodulatory, anti-inflammatory, and antiviral properties. The present article discusses the possibilities of LMN in SARS-CoV-2 infections based on its immunomodulatory, anti-inflammatory, and antiviral properties. Though, the suggestion on the possible use of LMN in COVID-19 remains inconclusive until the in-silico effects confirmed in the experimental studies and further proof of the concept studies. The candidature of LMN in COVID-19 treatment somewhat appear speculative but cannot be overlooked provided favorable physiochemical and druggable properties. The safety and efficacy of LMN are necessary to be established in preclinical and clinical studies before making suggestions for use in humans.
Collapse
Affiliation(s)
- M.F. Nagoor Meeran
- Department of Pharmacology and Therapeutics, College of Medicine and Health Sciences, PO Box - 17666, United Arab Emirates University, Al Ain, United Arab Emirates
| | - A. Seenipandi
- Department of Pharmacology and Therapeutics, College of Medicine and Health Sciences, PO Box - 17666, United Arab Emirates University, Al Ain, United Arab Emirates
| | - Hayate Javed
- Department of Anatomy, College of Medicine and Health Sciences, PO Box - 17666, United Arab Emirates University, Al Ain, United Arab Emirates
| | - Charu Sharma
- Department of Internal Medicine, College of Medicine and Health Sciences, PO Box - 17666, United Arab Emirates University, Al Ain, United Arab Emirates
| | - Hebaallah Mamdouh Hashiesh
- Department of Pharmacology and Therapeutics, College of Medicine and Health Sciences, PO Box - 17666, United Arab Emirates University, Al Ain, United Arab Emirates
| | - Sameer N. Goyal
- Shri Vile Parle Kelvani Mandal's Institute of Pharmacy, Dhule 424001, Maharashtra, India
| | - Niraj Kumar Jha
- Department of Biotechnology, School of Engineering & Technology, Sharda University, Knowledge Park III, Greater Noida, Uttar Pradesh 201310, India
| | - Shreesh Ojha
- Department of Pharmacology and Therapeutics, College of Medicine and Health Sciences, PO Box - 17666, United Arab Emirates University, Al Ain, United Arab Emirates
| |
Collapse
|
13
|
Shah S, Cristopher D, Sharma S, Soniwala M, Chavda J. Inhalable linezolid loaded PLGA nanoparticles for treatment of tuberculosis: Design, development and in vitro evaluation. J Drug Deliv Sci Technol 2020. [DOI: 10.1016/j.jddst.2020.102013] [Citation(s) in RCA: 11] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/11/2022]
|
14
|
Shah S, Ghetiya R, Soniwala M, Chavda J. Development and Optimization of Inhalable Levofloxacin Nanoparticles for The Treatment of Tuberculosis. Curr Drug Deliv 2020; 18:779-793. [PMID: 33155907 DOI: 10.2174/1567201817999201103194626] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/13/2020] [Revised: 08/08/2020] [Accepted: 09/24/2020] [Indexed: 02/06/2023]
Abstract
BACKGROUND Levofloxacin has been recommended by the WHO for the treatment of pulmonary tuberculosis and inhalable delivery of levofloxacin can be advantageous over conventional delivery. OBJECTIVE This study aimed to develop and optimize inhalable levofloxacin Loaded Chitosan Nanoparticles (LCN). The objective was to achieve the mean particle size of LCN less than 300nm, sustain the drug release up to 24 h, and achieve MMAD of LCN of less than 5μm. METHODS LCN were prepared by ionic gelation of chitosan with sodium tripolyphosphate (STPP) and subsequent lyophilization. A Plackett Burman screening design, 32 full factorial design, and overlay plots were sequentially employed to optimize the formulation. The mean particle size, % entrapment efficiency, in vitro drug release, and minimum inhibitory concentration were all evaluated. RESULTS The Pareto chart from the Placket Burman screening design revealed that the concentrations of chitosan and STPP was found to be significant (p < 0.05). Further analysis by 32 full factorial design revealed that F-ratio for each model generated was found to be greater than the theoretical value (p < 0.05), confirming the significance of each model. CONCLUSION The optimized formulation showed a mean particle size of 171.5 nm, sustained the drug release up to 24 h in simulated lung fluid, and revealed MMAD of 3.18 μm, which can confirm delivery of the drug to the deep lung region. However, further in vivo studies are required to design a suitable dosage regimen and establish the fate of nanoparticles for safe and efficacious delivery of the drug.
Collapse
Affiliation(s)
- Sunny Shah
- Bhagvanlal Kapoorchand Mody Government Pharmacy College, Rajkot, India
| | - Rohit Ghetiya
- Bhagvanlal Kapoorchand Mody Government Pharmacy College, Rajkot, India
| | | | - Jayant Chavda
- Bhagvanlal Kapoorchand Mody Government Pharmacy College, Rajkot, India
| |
Collapse
|
15
|
Pulmonary Delivery of Linezolid Nanoparticles for Treatment of Tuberculosis: Design, Development, and Optimization. J Pharm Innov 2020. [DOI: 10.1007/s12247-020-09491-9] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/01/2023]
|
16
|
Chen Y, Hong C, Chen X, Qin Z. Demethoxycurcumin increases the sensitivity of cisplatin-resistant non-small lung cancer cells to cisplatin and induces apoptosis by activating the caspase signaling pathway. Oncol Lett 2020; 20:209. [PMID: 32963615 PMCID: PMC7491090 DOI: 10.3892/ol.2020.12072] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/01/2020] [Accepted: 08/13/2020] [Indexed: 12/15/2022] Open
Abstract
Patients with non-small cell lung cancer (NSCLC) can develop strong drug resistance following long-term treatment with platinum-based drugs. Increasing doses of chemotherapeutic drugs fail to obtain better results, and serious complications occur. It has been demonstrated that upregulation of excision repair cross-complementary 1 (ERCC1) in lung cancer cells is closely associated with cell resistance to platinum-based chemotherapy. In addition, curcumin (CMN) enhances antitumor effects in NSCLC by downregulating ERCC1. The aim of the present study was to investigate the effects of demethoxycurcumin (DMC), a curcuminoid, on the reversal of resistance of NSCLC cells in vitro and in vivo. The present study demonstrated that DMC significantly increased the sensitivity of DDP in DDP-resistant A549 (A549/DDP) cells. The results from an MTT assay demonstrated that DMC combined with DDP significantly attenuated the proliferation of A549/DDP cells. Furthermore, DMC exhibited decreased toxicity in normal lung fibroblast MRC-5 cells. In addition, following treatment of A549/DDP cells with a combination of DMC and DDP, the expression of ERCC1 was reduced, the protein levels of Bcl-2 and Bax were decreased and increased, respectively, whereas caspase-3 was activated, according to results from western blotting. Finally, DDP combined with DMC significantly attenuated A549/DDP cell-derived tumor growth in vivo. Taken together, the findings from the present study suggested that DMC in combination with DDP may be considered as a novel combination regimen for restoring DDP sensitivity in DDP-resistant NSCLC cells.
Collapse
Affiliation(s)
- Yun Chen
- Department of Oncology, Zhejiang Provincial People's Hospital, People's Hospital of Hangzhou Medical College, Hangzhou, Zhejiang 310014, P.R. China
| | - Chaojin Hong
- Department of Oncology, Zhejiang Provincial People's Hospital, People's Hospital of Hangzhou Medical College, Hangzhou, Zhejiang 310014, P.R. China
| | - Xiaochen Chen
- Department of Oncology, Zhejiang Provincial People's Hospital, People's Hospital of Hangzhou Medical College, Hangzhou, Zhejiang 310014, P.R. China
| | - Zhiquan Qin
- Department of Oncology, Zhejiang Provincial People's Hospital, People's Hospital of Hangzhou Medical College, Hangzhou, Zhejiang 310014, P.R. China
| |
Collapse
|
17
|
Bampidis V, Azimonti G, Bastos MDL, Christensen H, Kos Durjava M, Kouba M, López‐Alonso M, López Puente S, Marcon F, Mayo B, Pechová A, Petkova M, Ramos F, Sanz Y, Villa RE, Woutersen R, Brantom P, Chesson A, Westendorf J, Gregoretti L, Manini P, Dusemund B. Safety and efficacy of turmeric extract, turmeric oil, turmeric oleoresin and turmeric tincture from Curcuma longa L. rhizome when used as sensory additives in feed for all animal species. EFSA J 2020; 18:e06146. [PMID: 32874324 PMCID: PMC7448085 DOI: 10.2903/j.efsa.2020.6146] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Following a request from the European Commission, the EFSA Panel on Additives and Products or Substances used in Animal Feed (FEEDAP) was asked to deliver a scientific opinion on the safety and efficacy of turmeric extract, turmeric oil, turmeric oleoresin and turmeric tincture from Curcuma longa L. rhizome when used as sensory additives in feed and in water for drinking for all animal species. The FEEDAP Panel concludes that the additives under consideration are safe at the maximum proposed use levels: (i) turmeric extract at 15 mg/kg complete feed (or in water for drinking at comparable exposure) for all animal species; (ii) turmeric essential oil at 80 mg/kg feed for veal calves (milk replacer) and 20 mg/kg complete feed (or 20 mg/L) for all other species; (iii) turmeric oleoresin at 30 mg/kg complete feed (or 30 mg/L) for chickens for fattening and laying hens and 5 mg/kg complete feed (or 5 mg/L) for pigs, veal calves, cattle for fattening and dairy cows, sheep, goats, horses, rabbits and fish; (iv) turmeric tincture at 0.8 mL/L water for drinking for poultry, 6 mL per head and day for horses and 0.05 mL tincture/kg complete feed for dogs. No concerns for consumers were identified following the use of the additives at the proposed use level in animal nutrition. Turmeric extract, turmeric oil, turmeric oleoresin and turmeric tincture should be considered as irritants to skin and eyes and the respiratory tract and as skin sensitisers. The use of the additives in feed is not expected to pose a risk for the environment. Since turmeric and its preparations are recognised to flavour food and their function in feed would be essentially the same as that in food, no further demonstration of efficacy is considered necessary.
Collapse
|